NCT03575351 · OUTCOME

Hospital Resource Utilization (HRU) Results

A Study to Compare the Efficacy and Safety of JCAR017 to Standard of Care in Adult Subjects With High-risk, Transplant-eligible Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphomas · Source last updated 2025-08-03

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure: COUNT_OF_PARTICIPANTS
Unit: Participants
Interval / dispersion: Not reported
Time frame: Up to 36 months

What was measured

Hospital resource utilization (HRU) results including hospitalized, reasons for hospitalizations, and admitted to intensive care unit (ICU)

Analysis population: All participants treated in any study medication

Groups in this outcome

Standard of Care Arm

3 cycles of standard of care (SOC) salvage therapy (R-DHAP, R-ICE and R-GDP) per physician's choice. Participants responding to SOC are expected to undergo high dose chemotherapy (HDCT) and hematopoietic stem cell transplant (HSCT). If requested by the investigator, participants may be allowed to receive JCAR017 upon meeting progression, relapse, or suboptimal response. 1 cycle = 3 weeks

Liso-cel Arm

\[Lymphodepleting chemotherapy (LDC)\] Fludarabine IV (30 mg/m\^2/day for 3 days) and cyclophosphamide IV (300 mg/m\^2/day for 3 days) followed by JCAR017 IV infusion at a dose of 100 x 10\^6 JCAR017-positive viable transduced T cells (CAR+ T cells) on Day 29 (2 to 7 days after completion of LD chemotherapy)

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

Group	Source count
Standard of Care Arm	91
Liso-cel Arm	92

Reported measurements

Hospitalized

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Standard of Care Arm	74	Not reported	Not reported	Not reported	Not reported
Liso-cel Arm	87	Not reported	Not reported	Not reported	Not reported

Hospitalized due to Adverse Event (AE)

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Standard of Care Arm	42	Not reported	Not reported	Not reported	Not reported
Liso-cel Arm	44	Not reported	Not reported	Not reported	Not reported

Hospitalized due to Progression of Disease

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Standard of Care Arm	2	Not reported	Not reported	Not reported	Not reported
Liso-cel Arm	6	Not reported	Not reported	Not reported	Not reported

Hospitalized per protocol

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Standard of Care Arm	11	Not reported	Not reported	Not reported	Not reported
Liso-cel Arm	22	Not reported	Not reported	Not reported	Not reported

Hospitalized due to other reasons

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Standard of Care Arm	56	Not reported	Not reported	Not reported	Not reported
Liso-cel Arm	71	Not reported	Not reported	Not reported	Not reported

Admitted to Intensive Care Unit (ICU)

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Standard of Care Arm	4	Not reported	Not reported	Not reported	Not reported
Liso-cel Arm	5	Not reported	Not reported	Not reported	Not reported

Complete source fields

classes

categories
measurements
group Id
OG000
value
74
group Id
OG001
value
87
title
Hospitalized
categories
measurements
group Id
OG000
value
42
group Id
OG001
value
44
title
Hospitalized due to Adverse Event (AE)
categories
measurements
group Id
OG000
value
2
group Id
OG001
value
6
title
Hospitalized due to Progression of Disease
categories
measurements
group Id
OG000
value
11
group Id
OG001
value
22
title
Hospitalized per protocol
categories
measurements
group Id
OG000
value
56
group Id
OG001
value
71
title
Hospitalized due to other reasons
categories
measurements
group Id
OG000
value
4
group Id
OG001
value
5
title
Admitted to Intensive Care Unit (ICU)

denoms

counts
group Id
OG000
value
91
group Id
OG001
value
92
units
Participants

description

Hospital resource utilization (HRU) results including hospitalized, reasons for hospitalizations, and admitted to intensive care unit (ICU)

groups

description
3 cycles of standard of care (SOC) salvage therapy (R-DHAP, R-ICE and R-GDP) per physician's choice. Participants responding to SOC are expected to undergo high dose chemotherapy (HDCT) and hematopoietic stem cell transplant (HSCT). If requested by the investigator, participants may be allowed to receive JCAR017 upon meeting progression, relapse, or suboptimal response. 1 cycle = 3 weeks
id
OG000
title
Standard of Care Arm
description
\[Lymphodepleting chemotherapy (LDC)\] Fludarabine IV (30 mg/m\^2/day for 3 days) and cyclophosphamide IV (300 mg/m\^2/day for 3 days) followed by JCAR017 IV infusion at a dose of 100 x 10\^6 JCAR017-positive viable transduced T cells (CAR+ T cells) on Day 29 (2 to 7 days after completion of LD chemotherapy)
id
OG001
title
Liso-cel Arm

param Type

COUNT_OF_PARTICIPANTS

population Description

All participants treated in any study medication

reporting Status

POSTED

time Frame

Up to 36 months

title

Hospital Resource Utilization (HRU) Results

type

SECONDARY

unit Of Measure

Participants

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Not medical advice